$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Medical drugs
Medical drugs
Medical drugs-Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Exploring the potential efficacy of olaparib in cancer patients with PALB2 gene mutations
2026-02-01 22:25:32
Check Details
Discussion on factors affecting survival of patients with BRCA mutated cancer treated with Lynparza
2026-02-01 22:25:32
Check Details
Full analysis of side effects during olaparib treatment, and how to effectively respond and manage them?
2026-02-01 22:25:32
Check Details
A new dawn in the treatment of BRCA-mutated breast cancer with Lynparza
2026-02-01 22:25:32
Check Details
Overview of erdafitinib price information and current market situation in China
2026-02-01 22:25:32
Check Details
Erdafitinib is not on the market in China, and patient access methods are being discussed
2026-02-01 22:25:32
Check Details
Erdafitinib drug introduction and overview of its indications
2026-02-01 22:25:32
Check Details
Domestic purchasing guide for erdafitinib: detailed explanation of price and versions
2026-02-01 22:25:32
Check Details
Discussion on the duration of treatment with regorafenib and its determinants
2026-02-01 22:25:32
Check Details
Comparison of global market prices of regorafenib in 2024: exploring the most economical way to purchase
2026-02-01 22:25:32
Check Details
How effective is regorafenib and what side effects should we pay attention to?
2026-02-01 22:25:32
Check Details
Scope of application and performance of regorafenib in the treatment of colorectal cancer
2026-02-01 22:25:32
Check Details
1
2
...
1004
1005
1006
1007
1008
1009
1010
...
2438
2439
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
New Research Progress on Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Tumor Relationship
2
Tyrosine Kinase and JAK Inhibitors May Increase Keratinocyte Carcinoma Risk: New Research Reveals Drug Safety Findings
3
CLISGen Database: A New Tool for Cell Line Selection in Cancer Genetic Variation Research
4
RAS Targeted Therapy Resistance Breakthrough: mTORC1 is Key, Dalifarnib Combination Therapy Brings Hope
5
ARID1A Gene: A New Breakthrough in Tumor Immunotherapy, Turning "Cold Tumors" Hot
6
User Agreement
7
Herceptin Hylecta treats HER2-positive breast cancer and only needs to be injected subcutaneously and only used once every three weeks
8
What is the most important information I should know about WELIREG?
9
How to take and store WELIREG
10
How to take TRUSELTIQ correctly
11
How to deal with LONSURF side effects (1)
12
How to deal with LONSURF side effects (2)